Kuick Research Report Gives In Depth Insight On More Than 600 CAR T Cell Therapies In Clinical Trials
Singapore, May 19, 2022 (GLOBE NEWSWIRE) -- Global CAR T Cell Therapy Market & Clinical Trials Insight 2028 Report Highlights:
-
Research Methodology
-
Global CAR T Cell Therapy Market Opportunity > USD 15 Billion
-
Global & Regional Market Insight: Current & Market Forecast 2028
-
Approved CAR T Cell Therapies Sales Forecast Till 2028
-
Emerging In Vivo Induced CAR T Cell Therapies
-
CAR T Cell Therapy Manufacturing Cost Analysis
-
CAR T Cell Therapy Approval & Reimbursement Scenario By Country
-
Patent, Price, Sales Insight On 6 Approved CAR T Cell Therapies
-
Insight On More Than 600 CAR T Cell Therapies In Clinical Trials
-
CAR T Cell Therapies Clinical Trials Insights by Company, Country & Phase
Download Report: https://www.kuickresearch.com/report-car-t-cell-therapy-market
Chimeric antigen receptor (CAR) T cell therapy has emerged out to revolutionary pillar in the management of cancer owing to its ability to produce durable clinical response. CARs are genetically engineered receptors proteins which provide novel T cells to target the specific protein present on the target cell. Once these genetically modified T cells are administered into the body, these serve as living drug against the target cells. Upon binding with the cells, they continue to proliferate and exhibit cytotoxic activities which ultimately lead to cell death. Owing to their novel mechanism of action, these have gained considerable interest among pharmaceutical giants.
Till date, cocktail of CAR T cell therapies have been granted approval by regulatory bodies which have been indicated for the management of hematological malignancies such as lymphoma, leukemia, and multiple myeloma. By therapeutic indication, lymphoma segment is currently dominating the global market which is mainly attributed to large number of drugs approved in particular indication associated with their robust sales. Kymriah was the first CAR T cell therapy which was approved for the management of diffuse large B-cell lymphoma. More recently, Breyanzi got approval in 2021 for the same therapeutic indication, thus fostering the growth of this segment.
Although CAR T cell therapy has shown success in the management of hematological malignancies, there are still challenges for their roles in solid tumors. Researchers are currently working to identify potential markers which can make CAR T an operative therapy in solid malignancies. A recent study has identified protein OR2H1 which has high expression in a variety of solid tumors. The novel protein is expressed about 4% in colon cancer samples to about 69% of cancers of the gall bladder. Under normal physiological condition, the protein is only expressed in testis, which suggests that targeting this receptor will have few side effects on the normal tissues. Therefore, it is believed that the coming years will witness translation of CAR T cell therapy in solid tumors which will drive the growth of market.